REBIRTHEL
Rebirthel aims to realize cell-based therapies against cancer or other immune-related diseases by using universal T cells that are regenerated from pluripotent stem cells.
REBIRTHEL
Industry:
Biotechnology Health Diagnostics Life Science Therapeutics
Founded:
2019-10-01
Address:
Kyoto, Kyoto, Japan
Country:
Japan
Website Url:
http://www.rebirthel.com
Total Employee:
1+
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Official Site Inspections
http://www.rebirthel.com
- Host name: www3143.sakura.ne.jp
- IP address: 49.212.207.183
- Location: Osaka Japan
- Latitude: 34.6848
- Longitude: 135.5142
- Timezone: Asia/Tokyo
- Postal: 543-0062
More informations about "Rebirthel"
リバーセル株式会社 | 汎用性即納型T細胞製剤を用いたがんの免疫 …
Rebirthel provides a novel treatment through a highly universal T cell preparation. Rebirthel was founded in October 2019 with the aim of providing novel treatments against cancer, infectious …See details»
Rebirthel
リバーセルは、多能性幹細胞からT細胞を再生することによって、大量に他家移植用のキラーT細胞を作製する技術を有しています。 この方法を用いて、がんを殺すことができるキラーT細 …See details»
Rebirthel - Crunchbase Company Profile & Funding
Rebirthel is a biotech company, focused on the development and operationalization of cell-based cancer immunotherapies. Rebirthel aims to realize cell-based therapies against cancer or …See details»
Rebirthel Company Profile 2024: Valuation, Funding & Investors
Developer of cellular immunotherapies intended to provide medical care for autoimmune diseases and cancer. The company generates innovative cell therapy by controlling the immune system …See details»
Rebirthel Co., Ltd. - BIO International Convention | BIO
Rebirthel Co., Ltd. will provide “allogeneic T cell therapy” using “off-the-shelf T cell preparations” to pioneer a new era of treating cancer and viral infectious diseases. We have multiple …See details»
Rebirthel Co.,Ltd. | LinkedIn
An independent biocompany, developing cellular immunotherapies for cancer, based on Kyoto. | Rebirthel aims to realize cell-based therapies against cancer or other immune-related …See details»
Introduction | Rebirthel
Apr 9, 2020 · Rebirthel Co., Ltd. was founded in October 2019, with the aim of developing and making available for patients a novel immune cell therapy for cancers using the technology …See details»
Rebirthel Co., Ltd. | Global Startup Acceleration Program (GSAP) …
Rebirthel provides a novel treatment "Allogeneic T cell therapy" using killer T cells regenerated from stem cells. Using stem cells instead of the patient's own cells reduces the patient burden. …See details»
リバーセル株式会社｜KBIC 神戸医療産業都市ポータルサイト
リバーセルは、京都大学医生物学研究所の河本宏所長・教授が開発した「多能性幹細胞からキラーT細胞を再生する技術」をベースに”超汎用性即納型T細胞製剤”を実現することで、これま …See details»
Rebirthel - Funding, Financials, Valuation & Investors - Crunchbase
Dec 1, 2022 · Rebirthel is a biotech company, focused on the development and operationalization of cell-based cancer immunotherapies.See details»
進出企業紹介 - KOBE BIOMEDICAL INNOVATION CLUSTER
Aug 31, 2024 · Rebirthel was founded in October 2019 with the aim of providing novel treatments against cancer, infectious diseases, and other immune-related diseases. Our strategy is based …See details»
Rebirthel - Company profile | ensun
Rebirthel opens the way to a future when patients go to hospital to receive transfusion of T cells to treat their disease. Rebirthel was founded in October 2019 with the aim of providing novel …See details»
Rebirthel - Products, Competitors, Financials, Employees, …
Rebirthelf focuses on the development of cell-based therapies, operating within the healthcare and biotechnology sectors. Use the CB Insights Platform to explore Rebirthel's full profile.See details»
Interviews with leading Life Sciences companies: Rebirthel
Nov 2, 2023 · Rebirthel are preparing the first clinical trial conducted in humans for acute myeloid leukemia to evaluate safety and efficacy. Learn more about the Kyoto-based organization in …See details»
Rebirthel was selected for subsidy program “Forest of Industry …
Aug 1, 2022 · As was the case last year, Rebirthel was selected honorably as one of the subsidized companies. Last year, we applied for the innovation development course. For this …See details»
Otsuka and Rebirthel Sign Licensing Agreement for iPSC-derived …
Dec 16, 2021 · Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that it entered into an exclusive commercial licensing agreement with Rebirthel Co., Ltd. (Rebirthel) for their …See details»
Rebirthel was selected for subsidy program “Forest of Industry …
Rebirthel has been selected as one of FY 2021 projects. Project title: Operationalization of cancer immunotherapy using off-the-shelf T cell preparation Project period: April 1 st , 2021 to …See details»
Otsuka Grabs Rights to Kyoto University Spinoff’s iPSC-Derived …
Dec 17, 2021 · Otsuka Pharmaceutical said on December 16 that it has earned the exclusive worldwide rights to Kyoto University startup Rebirthel’s genetically engineered cell production …See details»
News - Rebirthel
Rebirthel Co., Ltd. (Rebirthel) announced that it has entered into a strategic alliance agreeme... READ MORE NEWS 2023.5.29 Rebirthel signs collaborative research agreement for the …See details»
Rebirthel was introduced on the web magazine “Nikkei …
Aug 18, 2021 · Rebirthel appears in the article entitled “Rebirthel and Thyas: Development of universal T cell therapies using iPS cell”. The article explains that many startup companies are …See details»